Theracrine appoints new CEO

Theracrine Inc., a Cambridge biopharmaceutical company, announced the appointment of Steven Kelly as president and chief executive.

Theracrine is focused on developing drugs that stop cancer from spreading. According to Theracrine, so-called cancer spread is responsible for 90 percent of cancer-related deaths. The company was founded in 2010 by Flagship VentureLabs and cancer researchers.

Most recently, Kelly was the chief commercial officer for BioVex, which was sold to Amgen earlier this year in a transaction valued at $1 billion, Theracrine said in a press release.


This discussion has ended. Please join elsewhere on